Non-toxic agarose/gelatin-based microencapsulation system containing gallic acid for antifungal application

P. L. Lam  
*Hong Kong Polytechnic University*

R. Gambari  
*University of Ferrara*

S. H L Kok  
*The Chinese University of Hong Kong*

K. H. Lam  
*Hong Kong Polytechnic University*

J. C O Tang  
*Hong Kong Polytechnic University*

See next page for additional authors

Follow this and additional works at: [https://repository.hkbu.edu.hk/hkbu_staff_publication](https://repository.hkbu.edu.hk/hkbu_staff_publication)

Part of the Medicine and Health Sciences Commons

This document is the authors' final version of the published article.

Link to published article: [http://dx.doi.org/10.3892/ijmm.2014.2027](http://dx.doi.org/10.3892/ijmm.2014.2027)

**APA Citation**

Authors
Non-toxic agarose/gelatin-based microencapsulation system containing gallic acid for antifungal application

P.-L. LAM¹, R. GAMBARÍ², S.H.-L. KOK³, K.-H. LAM¹, J.C.-O. TANG¹, Z.-X. BIAN⁴, K.K.-H. LEE³ and C.-H. CHUI¹,⁴

¹State Key Laboratory of Chirosciences, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, SAR, P.R. China; ²Centre of Biotechnology, Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy; ³Ministry of Education (MOE) Key Laboratory for Regenerative Medicine, School of Biomedical Sciences, Chinese University of Hong Kong; ⁴Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, SAR, P.R. China

Received June 12, 2014; Accepted November 10, 2014

DOI: 10.3892/ijmm.2014.2027

Abstract. Aspergillus niger (A. niger) is a common species of Aspergillus molds. Cutaneous aspergillosis usually occurs in skin sites near intravenous injection and approximately 6% of cutaneous aspergillosis cases which do not involve burn or HIV-infected patients are caused by A. niger. Biomaterials and biopharmaceuticals produced from microparticle-based drug delivery systems have received much attention as microencapsulated drugs offer an improvement in therapeutic efficacy due to better human absorption. The frequently used crosslinker, glutaraldehyde, in gelatin-based microencapsulation systems is considered harmful to human beings. In order to tackle the potential risks, agarose has become an alternative polymer to be used with gelatin as wall matrix materials of microcapsules. In the present study, we report the eco-friendly use of an agarose/gelatin-based microencapsulation system to enhance the antifungal activity of gallic acid and reduce its potential cytotoxic effects towards human skin keratinocytes. We used optimal parameter combinations, such as an agarose/gelatin ratio of 1:1, a polymer/oil ratio of 1:60, a surfactant volume of 1% w/w and a stirring speed of 900 rpm. The minimum inhibitory concentration of microencapsulated gallic acid (62.5 μg/ml) was significantly improved when compared with that of the original drug (>750 μg/ml). The anti-A. niger activity of gallic acid-containing microcapsules was much stronger than that of the original drug. Following 48 h of treatment, skin cell survival was approximately 90% with agarose/gelatin microcapsules containing gallic acid, whereas cell viability was only 25-35% with free gallic acid. Our results demonstrate that agarose/gelatin-based microcapsules containing gallic acid may prove to be helpful in the treatment of A. niger-induced skin infections near intravenous injection sites.

Introduction

The Aspergillus species includes common saprophytic molds found worldwide (1). Skin diseases usually induced by a cutaneous manifestation of disseminated infection with Aspergillus fungi are known as cutaneous aspergillosis (2,3). Among the Aspergillus molds, Aspergillus niger (A. niger) is an abundant species of Aspergillus found in the environment. A. niger is a filamentous ascomycete fungus that has the potential to cause human diseases (4). Cutaneous aspergillosis usually occurs in the infected skin sites at or near intravenous injection sites and as for the cases of cutaneous aspergillosis which do not involve burn or HIV-infected patients, A. niger is responsible for approximately 6% of these cases (2). Recently, the concern for the safe use of biomaterials has increased worldwide. Microparticle-based drug delivery is under consideration as it promotes controlled drug release to improve the therapeutic performance of original drugs through human absorption (5). The microparticle system extends the drug circulation time in the body and improves the drug concentration in target tissues. This increases the therapeutic efficacy and reduces the frequency of drug administration (6).

Gelatin, as a biodegradable polymer, requires the use of the crosslinker, glutaraldehyde, to improve the strength of microcapsules (7). Since gelatin rapidly dissolves under aqueous conditions, its application in controlled drug delivery systems is considered difficult without the use of crosslinkers (8). Glutaraldehyde can promote an insoluble network within the wall matrix of microcapsules to reduce dissolution and...
Materials and methods

Materials. Agarose (type VII-A; gel point, 26±2°C at 1.5% gel; melting point, ≤65.5°C) and gelatin (derived from porcine skin, type A) were purchased from Sigma-Aldrich, Steinheim, Germany. Gallic acid (melting point, >200°C) was kindly provided by the China National Institute for the Control of Pharmaceutical and Biological Products, Beijing, China. Pure olive oil was obtained from Easy Creation Asia Ltd., Hong Kong, China. All the chemical reagents were supplied from Sigma-Aldrich.

Preparation of microcapsules. The method for microcapsule formation was as previously reported with slight modifications (5,15). Agarose and gelatin were hydrated in deionized water and mixed well together at 70-80°C. Gallic acid was titrated to pH 7 using 1% of NaOH. The titrated drug was poured into the agarose-gelatin mixture and continuously mixed for 10 min. Pure olive oil with 1% v/v Span 80 as a surfactant was added to the agarose-gelatin-drug mixture followed by continuous stirring to form the water in oil emulsion. The emulsion was then placed in a homogenizer (BioSpec Products, Bartlesville, OK, USA) to form the homogeneous emulsion. The emulsion was allowed to cool down to <25°C and continuously stirred for 3 h. The precipitates were washed with acetone. The resulting microcapsules were suction-filtered and stored in desiccators.

Determination of drug entrapment efficiency. Fifty milligrams of drug-containing microcapsules were dissolved in 100 ml of deionized water by heat. The samples were then filtered. The gallic acid content was analyzed by measuring the absorbance at 260 nm (λ<sub>max</sub> of drugs in deionized water) after suitable dilution using an UV/VIS spectrophotometer (Lambda 18; Perkin Elmer, Waltham, MA, USA). Each sample was analyzed in triplicate in order to obtain the mean entrapment efficiency. The drug entrapment efficiency was calculated using the following equation, as previously described (5):

\[
\text{Drug entrapment efficiency} = \frac{\text{Amount of calculated drug}}{\text{Amount of theoretical drug}} \times 100\%
\]

Surface morphology and particle size. Microcapsules were attached to the SEM stub using a twisted adhesive tape. The test samples were gold-coated prior to performing scanning electron microscopy (SEM) observation. The surface morphology of the drug-containing microcapsules was observed using a scanning electron microscope (JSM-6490LV; JEOL, Blackwood, NJ, USA). The particle size of the microcapsules was evaluated according to the captured SEM images. A total number of 500 microcapsules was counted manually, as previously described (5,7,15).

Fourier transform infrared spectroscopy (FTIR) analysis. In FTIR analysis, potassium bromide (KBr) was used as it has no pronounced absorption peaks over the mid-infrared band. In this section, 2 mg of samples were pelleted with 200 mg of KBr through the vacuum process. The chemical compositions of the developed microcapsules were examined using a
In vitro release study. For the in vitro release model of microcapsules containing gallic acid, a given amount of microcapsules was firstly suspended in 1,000 ml phosphate solution (pH 7.4) medium for 96 h and incubated at 100 rpm at room temperature. Aliquots were taken at desired time intervals. The drawn sample was filtered using filter paper and the residue was returned to the suspension medium. The clear filtrate of the drug-containing microcapsules was analyzed using a UV/VIS spectrophotometer (Perkin Elmer) for the determination of drug content, as previously described (5,7,15).

**Determination of minimum inhibitory concentrations (MICs).** Gallic acid was titrated to pH 7 to avoid too much acidity initially and improve the drug solubility. The conversion of gallic acid to a compound with the ketone group was believed to increase the antibacterial activity of the original drug. MICs of gallic acid-containing microcapsules and gallic acid were determined by the LB broth dilution method. *A. niger* in a concentration of 1x10^3 cells/ml was added to the test tubes. Various concentrations of gallic acid-containing microcapsules and gallic acid were added from a starting concentration of 1,000 µg/ml and were serially diluted. Terbinafine was employed as the positive control, while blank microcapsules (without drugs) were used as a negative control. Afterwards, they were incubated at 25°C for 48 h. The minimum concentrations of gallic acid-containing microcapsules and gallic acid that caused a complete growth inhibition towards microorganisms were recorded as MICs (15).

**Antifungal study.** *A. niger* in a concentration of 1x10^3 cells/ml was placed on agar plates. Filter papers were cut in a circular shape 1 cm in diameter. Paper stripes containing microencapsulated gallic acid and the free gallic acid at various concentrations were placed on the surface of the nutrient agar. Terbinafine (5 µg) was used as a positive control, while blank microcapsules without drugs were applied as a negative control. The plates were incubated in an incubator at 25°C for 2 days and the growth inhibitory effects of *A. niger* on the agar plates were recorded, as previously described (15).

**Cytotoxicity assay.** Human cells, including HaCaT skin keratinocytes were removed from 75 ml sterile cell culture flasks with trypsin and neutralized with fetal bovine serum. After washing with phosphate-buffered saline and centrifugation, the skin cells were re-suspended in complete cell culture medium at a concentration of approximately 1x10^5 cells/ml and counted manually using a haematocytometer under an inverted microscope. Human cells seeded in the 24 wells microtitre plates for 24 h were prepared for the screening of our microcapsules. Microcapsules containing 125 and 62.5 µg of gallic acid, blank microcapsules without drugs and 125 and 62.5 µg of free gallic acid were added and incubated with the cells for a further 48 h. Doxorubicin was used as a positive reference. The assessment of cytotoxicity was conducted using the sulforhodamine B protein staining method. Skin cells were fixed with trichloroacetic acid, washed with deionized water and stained with sulforhodamine B. Subsequently, the cells were washed again with acetic acid and the stained cells were dissolved in 100 ml unbuffered Tris-base. Finally, optical images of the skin keratinocytes were captured (Canon, Japan), as previously described (7,29).

**Statistical analyses.** The values are presented as the means ± standard deviation (SD), and statistical analyses were performed using a student t-test. The value of P<0.05 was considered to indicate a statistically significant difference.

**Results and Discussion**

**Optimization of agarose/gelatin-based microcapsules containing gallic acid**

**Effect of polymer ratio.** Microcapsule properties may be influenced by the polymer ratio during the formation process. It is vital for the determination of a suitable ratio between two wall polymeric materials (agarose and gelatin) as this may affect the effective entrapment of the core drug into the wall matrix of microcapsules. As shown in Fig. 1, the drug entrapment efficiency of microcapsules containing gallic acid achieved the highest level when the agarose to gelatin ratio was 1:1. It was also observed that the particle size of the microcapsules containing gallic acid was generally reduced with an increase in the gelatin ratio. Therefore, the agarose to gelatin ratio of 1:1 was determined to provide better physical properties for the formed microcapsules, with the highest drug entrapment efficiency and acceptable particle size, and this polymer ratio was used for the microcapsule synthesis for the remaining parameters.

**Effect of polymer to oil ratio.** The ratio of polymer to oil also determined the drug entrapment efficiency and particle size of the developed microcapsules. As shown in Fig. 2, microcapsules...
Effect of surfactant volume. The surfactant volume may also result in different drug entrapment efficiencies and particle sizes of microcapsules. Fig. 3 illustrates that the drug entrapment efficiency of the microcapsules containing gallic acid reached the highest level at 1% w/w of the surfactant volume and then decreased. The particle size of the microcapsules decreased when the surfactant volume was increased. This may be associated with a reduction in surface tension and force in the interface between the water phase and oil phase if the surfactant concentration was increased. The better stabilization of emulsified droplets with an increased surfactant input may avoid the aggregation and accumulation of small droplets during the microcapsule formation process (5). The surfactant volume was, consequently, selected as 1% v/v for producing the microcapsules with desirable drug entrapment efficiency and a suitable particle size.

Effect of stirring speed. The stirring speed also became a processing parameter that may differentiate the drug entrapment efficiency and particle size of the formed microcapsules. As shown in Fig. 4, it was observed that the drug entrapment efficiency of the microcapsules containing gallic acid generally increased from the stirring speed of 500 rpm and then reached the maximal level at 900 rpm. The particle size of the microcapsules decreased with the increment in stirring speed. This may be due to the fact that a faster stirring speed may break the w/o emulsion into smaller particle droplets and prohibit the smaller microcapsule from agglomerating during the microcapsule manufacturing process. However, a slower stirring speed may induce the cohesion of microparticles which accumulates to larger particles (5). Therefore, the selected stirring speed was 900 rpm so as to develop the microcapsules with the highest drug entrapment and acceptable particle size.

Drug entrapment efficiency, particle size and surface morphology of optimal microcapsules. The optimal mean drug entrapment efficiency of the microcapsules containing gallic acid was estimated to be 61.77±5.07%. The mean particle size of the gallic acid-loaded microcapsules was 22.73±6.43 µm. Fig. 5 illustrates the SEM image of the gallic acid-containing microcapsules. It was observed that they were approximately spherical in shape with a certain level of agglomerations.

FTIR analysis of microcapsules. In FTIR analysis, the diffuse reflectance measurement mode was applied in the range of wavelengths from 4,000 to 450 cm⁻¹ in wave numbers. The
infrared absorption spectra of the agarose/gelatin microcapsules containing gallic acid are shown in Fig. 6. Significant peaks were observed in the agarose spectrum at 2,940, 1,642 and 931 cm\(^{-1}\) that were related to C-H stretching, bonded H-O-H and 3,6-anhydrogalactose linkage, respectively (30). Gelatin showed the characteristic amide absorption bands at 1,656 and 1,540 cm\(^{-1}\) that referred to N-H stretching (5). Gallic acid exhibited the characteristic peaks at 3,496 cm\(^{-1}\) (O-H group), 1,705 cm\(^{-1}\) (carboxylic acids), 1,614 cm\(^{-1}\) (C=C stretching) and 1,265 cm\(^{-1}\) (C=O stretching) (5). The spectrum of the microcapsules containing gallic acid had the characteristic peaks of gallic acid, agarose and gelatin. The absorbances at 2,940 and 931 cm\(^{-1}\) displayed the C-H stretching and 3,6-anhydrogalactose linkage from agarose, respectively. The peak at 1,647 cm\(^{-1}\) revealed the presence of bonded H-O-H from agarose and N-H stretching from gelatin in the formed microcapsules. The characteristic peaks for gallic acid appeared in 3,496 cm\(^{-1}\) (O-H group), 1,705 cm\(^{-1}\) (carboxylic acids), 1,614 cm\(^{-1}\) (C=C stretching) and 1,265 cm\(^{-1}\) (C=O stretching).

Based on the FTIR results, it was revealed that the microcapsules contained the chemical ingredients and functional groups of the wall material (agarose and gelatin) and the core active agent (gallic acid). The overall results confirm the synthesis of the microcapsules containing gallic acid.

**In vitro release of microcapsules.** Fig. 7 illustrates the release profile of the microcapsules containing gallic acid. The percentage of drug release was investigated for 96 h in the *in vitro* controlled release model. Gallic acid was released gradually in the phosphate (pH 7.4) medium. After the first 6 h, it was observed that >15% of the drug was released from the microcapsules. After 24 h, approximately 40% of the drug was released. Another 13% of gallic acid was released after 48 h, and the release a 72 and 96 h was close to the plateau level.

### Table I. MICs of agarose/gelatin-based microcapsules containing gallic acid.

<table>
<thead>
<tr>
<th></th>
<th>MIC (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive control (Terbinafine)</td>
<td>1.25 µg/ml</td>
</tr>
<tr>
<td>Gallic acid</td>
<td>&gt;750 µg/ml</td>
</tr>
<tr>
<td>Microcapsules containing gallic acid</td>
<td>62.5 µg/ml</td>
</tr>
<tr>
<td>Blank microcapsules</td>
<td>Nil</td>
</tr>
</tbody>
</table>

MIC, minimum inhibitory concentrations; *A. niger, Aspergillus niger.*

---

Figure 6. Fourier transform infrared spectroscopy (FTIR) spectra of agarose/gelatin-based microcapsules containing gallic acid.

Figure 7. Release profile of agarose/gelatin-based microcapsules containing gallic acid.
Determination of MICs of microcapsules. The MICs demonstrated the lowest concentration of the microcapsules containing gallic acid and gallic acid allowing no growth of *A. niger* as shown in Table I. Terbinafine was used as a positive control. It was observed that the MIC of microencapsulated gallic acid (62.5 µg/ml) was greatly improved when compared to that of free gallic acid (>750 µg/ml). This may be due to the fact that the fungi normally take 48 h to grow and the agarose/gelatin wall matrix offered a relatively stable and sustained release of gallic acid. This may result in a continuous inhibitory effect of microencapsulated gallic acid towards *A. niger*.

Table II. Zone of clearance of agarose/gelatin-based microcapsules containing gallic acid towards *A. niger*.

<table>
<thead>
<tr>
<th>Dose</th>
<th>Gallic acid</th>
<th>Microcapsules containing gallic acid</th>
<th>Blank microcapsules</th>
<th>Terbinafine</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 µg</td>
<td>Nil</td>
<td>2.87±0.51</td>
<td>Nil</td>
<td></td>
</tr>
<tr>
<td>500 µg</td>
<td>Nil</td>
<td>6.37±0.64</td>
<td>Nil</td>
<td>19.33±0.93</td>
</tr>
<tr>
<td>1,000 µg</td>
<td>Nil</td>
<td>9.17±0.35</td>
<td>Nil</td>
<td></td>
</tr>
</tbody>
</table>

Results are shown as the means ± SD. *A. niger, Aspergillus niger; SD, standard deviation.*

Figure 8. Growth inhibitory effects towards *Aspergillus niger*: (A) free gallic acid; (B) microcapsules containing gallic acid; (C) blank microcapsules (negative control); and (D) 5 µg terbinafine (positive control).

Antifungal activity of microcapsules. Fig. 8 and Table II show the dose-dependent response of microencapsulated gallic acid to *A. niger* activity. Microcapsules containing 1,000 µg of gallic acid (inhibitory zone, 9.17±0.35 mm) had the strongest anti-*A. niger* activity, followed by microcapsules with 500 µg (inhibitory zone, 6.37±0.64 mm) and 250 µg (inhibitory zone, 2.87±0.51 mm) of gallic acid. However, free gallic acid did not show any growth inhibitory effects towards *A. niger*, similar to the blank microcapsules (negative control). It was speculated that the free drug may reduce the fungal growth at the beginning. The noticeably stronger antifungal activity of microencapsulated gallic acid may be due to the prolonged drug release from the microcapsules which provided a continuous inhibitory effect towards the fungal cells which grew relatively slow within 48 h.

Figure 9. Inhibitory effects towards human skin keratinocytes: (A) blank control microcapsules; (B) 2 µg/ml doxorubicin; (C) microcapsules containing 62.5 µg/ml gallic acid; (D) microcapsules containing 125 µg/ml gallic acid; (E) 62.5 µg/ml gallic acid; and (F) 125 µg/ml gallic acid.
Cytoxicity of microcapsules. As shown in Fig. 9, it was observed that the microcapsules containing gallic acid at a dose of 62.5 µg/ml (Fig. 9C) and 125 µg/ml (Fig. 9D) did not induce cell death. Morphologically, microcapsules containing gallic acid at a dose if 62.5 µg/ml (Fig. 9C) and 125 µg/ml (Fig. 9D) also showed a normal cellular morphology, similar to the blank control microcapsules (Fig. 9A). The microcapsules containing gallic acid also exhibited a similar effect on cell viability (Fig. 10) to the untreated controls and blank control microcapsules; cell survival was >90% following treatment with microcapsules containing gallic acid at 62.5 µg/ml and approximately 90% following treatment with microcapsules containing gallic acid at 125 µg/ml. Free gallic acid at the concentration of 62.5 µg/ml (Fig. 9E) and 125 µg/ml (Fig. 9F), however, induced significant cell death, indicated by nuclear condensation, cell shrinkage and detachment from the substratum. As shown in Fig. 10, cell viability following treatment with free gallic acid at 62.5 and 125 µg/ml was approximately 35% and 25%, respectively when compared with the untreated controls. Doxorubicin at 2 µg/ml (Fig. 9B) was used as a positive control to induce HaCaT skin keratinocyte cell death. The blank control microcapsules did not inhibit cell proliferation or induce cell death.

Polymeric microcapsules have been widely applied for drug delivery in order to improve the therapeutic performance of original drugs. Cutaneous aspergillosis is generally caused by *Aspergillus* fungi and it can be associated with *A. niger*, which leads to skin infections at or near intravenous injection sites. In order to utilize the biological effects of therapeutic agents, microencapsulation is considered a feasible method since the concentration of microencapsulated drugs in the targeted body sites can be modulated in a controlled manner. The drug bioavailability can also be improved with the aid of the microparticle delivery system, as microencapsulated drugs increase the stability, safety and efficacy of the original drugs, and therefore improve the therapeutic effects of drug treatment and promote patient compliance and convenience of administration. Recently, we reported the use of an agar/gelatin-based microencapsulation system to deliver gallic acid for hepatoprotective application (5) and to deliver *Phyllanthus urinaria* for antifungal purposes (15). In order to enhance the potential antifungal activity of gallic acid in the microencapsulation system, agarose was used instead of agar in the gelatin-based system due to the stronger mechanical properties of the agarose gel network. The development, characterization and biological activities of the agarose/gelatin-based microcapsules containing gallic acid were demonstrated in this study. The involvement of agarose as the wall matrix materials with gelatin aimed at strengthening the wall of the formed microcapsules and avoiding the potential toxicity of using the hazardous crosslinking agent, glutaraldehyde. The development of an optimal microencapsulation recipe without the use of glutaraldehyde may promote the desired properties of microcapsules due to its biological safety and economic advantages in microcapsule formation. Our results revealed that microencapsulated gallic acid markedly improved the antifungal activity towards *A. niger*, but also greatly reduced the cytotoxic effects towards human skin keratinocytes when compared with the original drug. Therefore, it was speculated that the development of biologically safe agarose/gelatin-based microcapsules containing gallic acid may be a potent device for the treatment of cutaneous aspergillosis.

Acknowledgements

This study was supported by the Innovative Technology Commission, HKPU, and the accounts of 38-40-116 (C.H.C.) and 03-16-176 (X.Z.B.). We also acknowledge the financial support from the research fund of Ministry of Education (MOE) Key Laboratory for Regenerative Medicine, School of Biomedical Sciences, Chinese University of Hong Kong (K.K.-H.L.).

References